Stable scFv Antibodies for TNFα Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TNFα-associated disorders, such as rheumatoid arthritis, lack effective and flexible administration forms with optimal functional properties for continuous treatment and improved tissue penetration.
Innovation Solution
Development of stable and soluble scFv antibodies and Fab fragments specifically designed for TNFα binding, optimized for stability, solubility, and low immunogenicity, which can be used for diagnosis and treatment of TNFα-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current TNFα blocking agents are administered as intravenous or subcutaneous bolus injections, then high starting concentrations are achieved, but the treatment lacks flexibility and continuous therapeutic effect
Solution Approach 1:
The patent develops antibody formulations with optimized pharmacokinetic properties that enable dynamic, continuous therapeutic effect rather than static bolus injection peaks and valleys. The engineered antibodies maintain stable blood concentrations over extended periods, providing continuous TNFα blockade while allowing flexible administration schedules.
Solution Approach 2:
The invention modifies key pharmacokinetic parameters of anti-TNFα antibodies, including half-life, volume of distribution, and clearance rate. By engineering antibodies with altered stability and solubility characteristics, the formulation achieves prolonged duration of action while enabling flexible dosing intervals, resolving the contradiction between continuous effect and administration flexibility.
2Reliability
If traditional antibody formulations are used, then proven efficacy is achieved, but tissue penetration and volume of distribution are limited
Solution Approach 1:
The patent engineers antibodies with modified physical-chemical parameters including reduced molecular size, optimized charge distribution, and altered hydrophobicity. These parameter changes enhance tissue penetration and expand volume of distribution while preserving the antibody's ability to bind and neutralize TNFα, thereby maintaining therapeutic efficacy.
Solution Approach 2:
The invention introduces heterogeneity in antibody properties, creating formulations with diverse molecular characteristics that can penetrate different tissue compartments effectively. The engineered antibodies possess localized modifications that facilitate deep tissue penetration while maintaining overall binding affinity and therapeutic reliability.
3Stability of the object's composition
If antibody stability is increased for prolonged treatment, then continuous therapeutic effect is achieved, but solubility may be compromised
Solution Approach 1:
The patent employs rational protein engineering to modify amino acid sequences of the antibody, introducing stabilizing mutations that enhance thermal and proteolytic stability without compromising solubility. The engineered antibodies achieve enhanced composition stability for prolonged treatment while maintaining adequate solubility through balanced molecular design.
Solution Approach 2:
The invention creates composite antibody formulations combining engineered monoclonal antibodies with excipients and stabilizing agents. This composite approach enhances both stability and solubility simultaneously, allowing prolonged therapeutic effect while ensuring adequate dissolution and bioavailability.
Data Source
AI summary
The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.